{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:25:51Z","timestamp":1758169551254,"version":"3.44.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbcan.2025.189408","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:26:26Z","timestamp":1754450786000},"page":"189408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy"],"prefix":"10.1016","volume":"1880","author":[{"given":"Francesco","family":"Gentile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Cros-Perrial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3948-7090","authenticated-orcid":false,"given":"Lars Petter","family":"Jordheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189408_bb0005","first-page":"414","article-title":"DNA direct reversal repair and alkylating agent drug resistance","volume":"4","author":"Gutierrez","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.bbcan.2025.189408_bb0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189408_bb0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BST20210246","article-title":"Mechanism of action of nucleotide excision repair machinery","volume":"50","author":"D\u2019Souza","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbcan.2025.189408_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/genes16020231","article-title":"Nucleotide excision repair: insights into canonical and emerging functions of the transcription\/DNA repair factor TFIIH","volume":"16","author":"Zachayus","year":"2025","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103728","article-title":"Protein-protein interactions in the core nucleotide excision repair pathway","volume":"141","author":"D\u2019Souza","year":"2024","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0030","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1038\/s41467-024-52860-y","article-title":"Molecular architecture and functional dynamics of the pre-incision complex in nucleotide excision repair","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189408_bb0035","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.3390\/ijms232315410","article-title":"Revisiting the anti-cancer toxicity of clinically approved platinating derivatives","volume":"23","author":"Forgie","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189408_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076397","article-title":"Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to carboplatin but is absent in carboplatin-resistant cells","volume":"8","author":"Brozovic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189408_bb0045","doi-asserted-by":"crossref","first-page":"7449","DOI":"10.1038\/sj.onc.1208047","article-title":"Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA","volume":"23","author":"Gourdier","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189408_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100633","article-title":"Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin","volume":"296","author":"Sutton","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189408_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2016.01.010","article-title":"Cisplatin binding to proteins: a structural perspective","volume":"315","author":"Messori","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bbcan.2025.189408_bb0060","series-title":"GeneReviews((R))","article-title":"Xeroderma Pigmentosum","author":"Kraemer","year":"1993"},{"key":"10.1016\/j.bbcan.2025.189408_bb0065","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/carcin\/21.3.453","article-title":"Nucleotide excision repair and human syndromes","volume":"21","author":"de Boer","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2025.189408_bb0070","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1007\/s00018-021-03984-7","article-title":"Nucleotide excision repair leaves a mark on chromatin: DNA damage detection in nucleosomes","volume":"78","author":"Apelt","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2025.189408_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1086\/512486","article-title":"First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure","volume":"80","author":"Jaspers","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2025.189408_bb0080","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ajhg.2013.04.007","article-title":"Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia","volume":"92","author":"Kashiyama","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2025.189408_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000871","article-title":"Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients","volume":"6","author":"Ahmad","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbcan.2025.189408_bb0090","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/hmg\/7.6.969","article-title":"Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms","volume":"7","author":"Matsumura","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbcan.2025.189408_bb0095","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ygyno.2019.02.014","article-title":"ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers","volume":"153","author":"Mesquita","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Arora","year":"2010","journal-title":"DNA Repair (Amst)"},{"issue":"75104\u201375117","key":"10.1016\/j.bbcan.2025.189408_bb0110","article-title":"Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells","volume":"7","author":"Arora","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189408_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116885","article-title":"SLX4 and XPF are involved in cell migration and EMT in a cell-specific manner","volume":"236","author":"Cros-Perrial","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0120","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41467-020-14564-x","article-title":"Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189408_bb0125","doi-asserted-by":"crossref","first-page":"55246","DOI":"10.18632\/oncotarget.19422","article-title":"Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189408_bb0130","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.21873\/anticanres.14301","article-title":"Characteristics of gastric carcinomas with high ERCC1 expression and the prognostic value of ERCC1 expression","volume":"40","author":"Yang","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/cancers11081149","article-title":"ERCC1 is a predictor of anthracycline resistance and Taxane sensitivity in early stage or locally advanced breast cancers","volume":"11","author":"Abdel-Fatah","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0140","doi-asserted-by":"crossref","first-page":"8410670","DOI":"10.1155\/tbj\/8410670","article-title":"Predictive value of excision repair cross complementation group 1 (ERCC1) by immunohistochemistry for determining neoadjuvant chemotherapy response in triple-negative breast cancers","volume":"2025","author":"Hashmi","year":"2025","journal-title":"Breast J."},{"key":"10.1016\/j.bbcan.2025.189408_bb0145","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.4161\/cc.26309","article-title":"ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform","volume":"12","author":"Friboulet","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2025.189408_bb0150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0155","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0160","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMc070742","article-title":"ERCC1 and non-small-cell lung cancer","volume":"356","author":"Niedernhofer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0165","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMc072007","article-title":"ERCC1-specific immunostaining in non-small-cell lung cancer","volume":"357","author":"Olaussen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0170","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/bjc.2013.576","article-title":"ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial","volume":"109","author":"Bauman","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189408_bb0175","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.21873\/anticanres.15046","article-title":"ERCC1 is a predictive biomarker for non-small cell lung cancer but is antibody-dependent","volume":"41","author":"Okimoto","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0180","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/srep04313","article-title":"Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody","volume":"4","author":"Smith","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189408_bb0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.5858\/arpa.2016-0006-OA","article-title":"Development and validation of an ERCC1 immunohistochemistry assay for solid tumors","volume":"140","author":"Bahamon","year":"2016","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.dnarep.2018.02.002","article-title":"A novel antibody-based approach to detect the functional ERCC1-202 isoform","volume":"64","author":"Kuo","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0195","first-page":"226","article-title":"A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer. Glob","volume":"3","author":"Oishi","year":"2021","journal-title":"Health Med."},{"key":"10.1016\/j.bbcan.2025.189408_bb0200","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-18-3094","article-title":"Identification and characterization of synthetic viability with ERCC1 deficiency in response to Interstrand crosslinks in lung cancer","volume":"25","author":"Heyza","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0205","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1158\/1078-0432.CCR-18-4123","article-title":"The \u201cguardian of the genome\u201d-an old key to unlock the ERCC1 issue","volume":"25","author":"Friboulet","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.13043","article-title":"The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent","volume":"39","author":"Ciniero","year":"2025","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac045","article-title":"ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe","volume":"5","author":"Heyza","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bbcan.2025.189408_bb0220","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/1541-7786.MCR-16-0094","article-title":"Ercc1 deficiency promotes tumorigenesis and increases cisplatin sensitivity in a Tp53 context-specific manner","volume":"14","author":"Jokic","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0225","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0230","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.1093\/nar\/gkv934","article-title":"CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene","volume":"43","author":"Liu","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neo.2017.01.007","article-title":"Reactivating p53 and inducing tumor apoptosis (RITA) enhances the response of RITA-sensitive colorectal cancer cells to chemotherapeutic agents 5-fluorouracil and Oxaliplatin","volume":"19","author":"Wiegering","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2025.189408_bb0240","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/cancers15030997","article-title":"PARP inhibitors and proteins interacting with SLX4","volume":"15","author":"Jordheim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0245","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1093\/nar\/gkq1304","article-title":"Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells","volume":"39","author":"Zhang","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0250","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/carcin\/bgs393","article-title":"PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells","volume":"34","author":"Cheng","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2025.189408_bb0255","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1038\/onc.2013.311","article-title":"A high-throughput screen identifies PARP1\/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer","volume":"32","author":"Postel-Vinay","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189408_bb0260","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189408_bb0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2019.10.035","article-title":"PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers","volume":"469","author":"Ali","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189408_bb0270","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.112.082347","article-title":"Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells","volume":"84","author":"Jordheim","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.isci.2019.05.017","article-title":"ERCC1\/XPF is important for repair of DNA double-strand breaks containing secondary structures","volume":"16","author":"Li","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2025.189408_bb0280","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd.2018.77","article-title":"Cryo-EM in drug discovery: achievements, limitations and prospects","volume":"17","author":"Renaud","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189408_bb0285","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189408_bb0290","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41467-020-14856-2","article-title":"Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation","volume":"11","author":"Jones","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189408_bb0295","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.str.2005.08.014","article-title":"The structure of the human ERCC1\/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair","volume":"13","author":"Tripsianes","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.bbcan.2025.189408_bb0300","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","article-title":"DrugBank: a knowledgebase for drugs, drug actions and drug targets","volume":"36","author":"Wishart","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0305","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1093\/nar\/26.18.4146","article-title":"Mapping of interaction domains between human repair proteins ERCC1 and XPF","volume":"26","author":"de Laat","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0310","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1093\/nar\/24.17.3370","article-title":"Mutational analysis of the human nucleotide excision repair gene ERCC1","volume":"24","author":"Sijbers","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0315","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/cells12111475","article-title":"XPF-ERCC1 blocker improves the therapeutic efficacy of 5-FU- and Oxaliplatin-based Chemoradiotherapy in colorectal cancer","volume":"12","author":"Huang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189408_bb0320","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1021\/acs.jmedchem.5b01684","article-title":"Role of molecular dynamics and related methods in drug discovery","volume":"59","author":"De Vivo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189408_bb0325","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1021\/acs.jmedchem.9b00326","article-title":"Targeting DNA repair in tumor cells via inhibition of ERCC1-XPF","volume":"62","author":"Elmenoufy","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189408_bb0330","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/cbdd.13660","article-title":"Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction","volume":"95","author":"Gentile","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbcan.2025.189408_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112658","article-title":"Design, synthesis and in vitro cell-free\/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway","volume":"204","author":"Elmenoufy","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189408_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.819172","article-title":"Modulation of ERCC1-XPF Heterodimerization inhibition via structural modification of small molecule inhibitor side-chains","volume":"12","author":"Weilbeer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-020-04213-x","article-title":"Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair","volume":"87","author":"Ciniero","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0350","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s13346-024-01782-9","article-title":"Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics","author":"Mehinrad","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.dnarep.2015.04.002","article-title":"Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance","volume":"31","author":"McNeil","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0360","doi-asserted-by":"crossref","first-page":"91","DOI":"10.55730\/1300-0152.2686","article-title":"A novel algorithm for the virtual screening of extensive small molecule libraries against ERCC1\/XPF protein-protein interaction for the identification of resistance-bypassing potential anticancer molecules","volume":"48","author":"Ghazy","year":"2024","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0365","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/ijms25021246","article-title":"Unveiling novel ERCC1-XPF complex inhibitors: bridging the gap from in silico exploration to experimental design","volume":"25","author":"Manguinhas","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189408_bb0370","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0375","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/1440-1681.12282","article-title":"Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability","volume":"41","author":"Jordheim","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0380","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.bmcl.2015.08.031","article-title":"Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF","volume":"25","author":"Chapman","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2025.189408_bb0385","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.bmcl.2015.08.024","article-title":"N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF","volume":"25","author":"Chapman","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2025.189408_bb0390","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/nu10111644","article-title":"Targeting the DNA repair endonuclease ERCC1-XPF with Green tea polyphenol Epigallocatechin-3-Gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells","volume":"10","author":"Heyza","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.bbcan.2025.189408_bb0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jphs.2015.04.003","article-title":"EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells","volume":"128","author":"Hu","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2025.189408_bb0400","article-title":"EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189408_bb0405","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/tox.22284","article-title":"Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT\/STAT3 pathway and suppressing multidrug resistance 1 signaling","volume":"32","author":"Yuan","year":"2017","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0410","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.3390\/cells11233723","article-title":"The XPA protein-life under precise control","volume":"11","author":"Krasikova","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189408_bb0415","first-page":"4529","article-title":"Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins","volume":"59","author":"Jiang","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0420","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/sj.emboj.7601894","article-title":"Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA","volume":"26","author":"Tsodikov","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2025.189408_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051329","article-title":"Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction","volume":"7","author":"Barakat","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2025.189408_bb0430","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300648","article-title":"Small molecule antagonists of the DNA repair ERCC1\/XPA protein-protein interaction","volume":"19","author":"Obermann","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbcan.2025.189408_bb0435","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1021\/cb1000444","article-title":"Identification of novel small molecule inhibitors of the XPA protein using in silico based screening","volume":"5","author":"Neher","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0440","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1021\/acs.jmedchem.7b00780","article-title":"Design and structure-guided development of novel inhibitors of the Xeroderma Pigmentosum group a (XPA) protein-DNA interaction","volume":"60","author":"Gavande","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189408_bb0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.8465201","article-title":"DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor","volume":"260","author":"Schaeffer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189408_bb0450","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"21","author":"Alekseev","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0455","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/gtc.12674","article-title":"Spironolactone-induced XPB degradation depends on CDK7 kinase and SCF(FBXL18) E3 ligase","volume":"24","author":"Ueda","year":"2019","journal-title":"Genes Cells"},{"key":"10.1016\/j.bbcan.2025.189408_bb0460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/15384101.2020.1860559","article-title":"Spironolactone-induced XPB degradation requires TFIIH integrity and ubiquitin-selective segregase VCP\/p97","volume":"20","author":"Chauhan","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2025.189408_bb0465","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/leu.2017.182","article-title":"Nucleotide excision repair is a potential therapeutic target in multiple myeloma","volume":"32","author":"Szalat","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbcan.2025.189408_bb0470","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/1535-7163.MCT-21-0613","article-title":"A preclinical study to repurpose spironolactone for enhancing chemotherapy response in bladder cancer","volume":"21","author":"Xu","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189408_bb0475","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1158\/1078-0432.CCR-23-0673","article-title":"Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma","volume":"29","author":"Lal","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0480","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jid.2018.07.039","article-title":"Spironolactone depletes the XPB protein and inhibits DNA damage responses in UVB-irradiated human skin","volume":"139","author":"Kemp","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0485","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/ijms22041638","article-title":"Inhibitors of nucleotide excision repair decrease UVB-induced mutagenesis-An in vitro study","volume":"22","author":"Fidrus","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189408_bb0490","article-title":"Replication protein a: a multifunctional protein with roles in DNA replication, repair and beyond. NAR","volume":"2","author":"Dueva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189408_bb0495","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207408119","article-title":"Two interaction surfaces between XPA and RPA organize the preincision complex in nucleotide excision repair","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2025.189408_bb0500","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.385.3.4","article-title":"Development of a high-throughput screen for inhibitors of replication protein a and its role in nucleotide excision repair","volume":"3","author":"Andrews","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189408_bb0505","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/304035","article-title":"Targeting the OB-folds of replication protein a with small molecules","volume":"2010","author":"Anciano Granadillo","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/j.bbcan.2025.189408_bb0510","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1535-7163.MCT-11-0303","article-title":"Novel irreversible small molecule inhibitors of replication protein a display single-agent activity and synergize with cisplatin","volume":"10","author":"Neher","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189408_bb0515","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-09-3422","article-title":"Targeted inhibition of replication protein a reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function","volume":"70","author":"Shuck","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0520","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcp.2014.10.013","article-title":"Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer","volume":"93","author":"Mishra","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0525","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/acsmedchemlett.9b00440","article-title":"Structure-guided optimization of replication protein A (RPA)-DNA interaction inhibitors","volume":"11","author":"Gavande","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2025.189408_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.826655","article-title":"In Vivo targeting replication protein a for cancer therapy","volume":"12","author":"VanderVere-Carozza","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0535","doi-asserted-by":"crossref","first-page":"9943","DOI":"10.1093\/nar\/gkaa688","article-title":"The crystal structure of human XPG, the xeroderma pigmentosum group G endonuclease, provides insight into nucleotide excision DNA repair","volume":"48","author":"Gonzalez-Corrochano","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0540","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.3390\/cancers16183174","article-title":"Novel DNA repair inhibitors targeting XPG to enhance cisplatin therapy in non-small cell lung cancer: insights from in silico and cell-based studies","volume":"16","author":"Manguinhas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0545","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nature05456","article-title":"A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis","volume":"444","author":"Niedernhofer","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189408_bb0550","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/0008-5472.CAN-21-3798","article-title":"An active learning framework improves tumor variant interpretation","volume":"82","author":"Blee","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189408_bb0555","article-title":"A comparative survey of deep active learning","author":"Zhan","year":"2022","journal-title":"arXiv"},{"key":"10.1016\/j.bbcan.2025.189408_bb0560","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcae013","article-title":"XPA tumor variant leads to defects in NER that sensitize cells to cisplatin","volume":"6","author":"Blee","year":"2024","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bbcan.2025.189408_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100034","article-title":"Single-arm, open label prospective trial to assess prediction of the role of ERCC1\/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy","volume":"6","author":"Ganzinelli","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2025.189408_bb0570","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/cancers12092398","article-title":"Impact of ERCC1, XPF and DNA polymerase beta expression on platinum response in patient-derived ovarian cancer xenografts","volume":"12","author":"Guffanti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2025.189408_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.850883","article-title":"Recent advances in the development of non-PIKKs targeting small molecule inhibitors of DNA double-strand break repair","volume":"12","author":"Kelm","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0580","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/1400","article-title":"Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA","volume":"5","author":"Ikegami","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bbcan.2025.189408_bb0585","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/emboj\/20.3.612","article-title":"Structure of the major single-stranded DNA-binding domain of replication protein a suggests a dynamic mechanism for DNA binding","volume":"20","author":"Bochkareva","year":"2001","journal-title":"EMBO J."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:19:26Z","timestamp":1758143966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0304419X25001507"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189408","relation":{},"ISSN":["0304-419X"],"issn-type":[{"type":"print","value":"0304-419X"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189408"}}